Researchers check how well the RSV shot protects seniors over time
NCT ID NCT06077968
Summary
This study aims to understand how well the ABRYSVO vaccine works in the real world to prevent severe RSV infections in adults aged 60 and older. Researchers will analyze existing health records over several years to see how effective the vaccine is at preventing hospitalizations and emergency visits. The study will also look at how long protection lasts and if a second dose provides additional benefit.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUSES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.